Patients with the JAK2 mutation often present with varied clinical features, such as erythrocytosis, leukocytosis, or thrombocytosis, and have an increased risk of complications like thrombosis and disease progression [5,6]. The gene discussed is JAK2; the disease is deep vein thrombosis.